FDA sends Procter & Gamble a warning

Sep 18, 2007

The U. S. Food and Drug Administration has warned the Procter & Gamble Co. about claims it makes for its Vicks Early Defense Foaming Hand Sanitizer.

The agency said the product's claims and directions for use cause it to be an unapproved new drug under the Federal Food, Drug, and Cosmetic Act.

The FDA specifically citied P&G for promoting Early Defense for use by schoolchildren to prevent colds and to provide antimicrobial activity for up to three hours. Officials said the product has not been proven safe and effective for such claims.

Under its drug monograph system, the FDA allows OTC drugs to be marketed without first obtaining agency approval in certain circumstances. Such drugs must comply with applicable standards regarding monographs that specify conditions for the drugs' labeling and formulation.

In the Procter & Gamble case, the Cincinnati-headquartered company's claims the product prevents colds and provides up to three hours of antimicrobial activity are not allowed.

Copyright 2007 by United Press International

Explore further: Radiologist recommendations for chest CT have high clinical yield

add to favorites email to friend print save as pdf

Related Stories

Drugmakers eliminate infant drops of key medicine

May 05, 2011

(AP) -- Johnson & Johnson and other makers of cold and fever medications said Wednesday that they will discontinue infant drops of medicines containing acetaminophen in an effort to avoid confusion that can lead to dangerous ...

FDA warns of fractures with osteoporosis drugs

Oct 13, 2010

(AP) -- Government health officials warned doctors and patients Wednesday about an increased risk of thigh fractures with a widely used group of bone-strengthening drugs.

FDA looks to curb abuse of cough medicine

Aug 31, 2010

(AP) -- Federal health regulators are weighing restrictions on Robitussin, NyQuil and other cough suppressants to curb cases of abuse that send thousands of people to the hospital each year.

Recommended for you

New approach to particle therapy dosimetry

Dec 19, 2014

Researchers at the National Physical Laboratory (NPL), in collaboration with EMRP partners, are working towards a universal approach to particle beam therapy dosimetry.

Supplement maker admits lying about ingredients

Dec 17, 2014

Federal prosecutors say the owner and president of a dietary supplement company has admitted his role in the sale of diluted and adulterated dietary ingredients and supplements sold by his company.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.